Cobepa Makes Growth Investment in Reaction Biology
March 16, 2022
Cobepa S.A. completed a growth investment in Reaction Biology to support expansion of the CRO's drug discovery capabilities and global footprint. The transaction includes financing from Golub Capital and coincides with the appointment of John H. Johnson as Reaction Biology's CEO.
- Buyers
- Cobepa S.A.
- Targets
- Reaction Biology
- Industry
- Healthcare Services
- Location
- Pennsylvania, United States
- Transaction Type
- Growth capital
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.